In a prospective cohort study of patients with first-ever AIS, nearly half of the statin-treated individuals exhibited elevated Lp(a) levels during follow-up compared to baseline, which correlated with recurrent vascular events despite achieving LDL cholesterol targets [97]. Here, LPA is linked to androgen insensitivity syndrome.